Gilead's lung cancer bid for Trodelvy hits wall, but HIV studies deliver better news

FierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program

FierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing deal

FierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637M

Endpoints NewsEndpoints Women in Biopharma: Nominate for 2026

Lonza NewsAmMax Bio licenses ADC technology from Lonza - The Pharma Letter

FDA News ReleasesFDA Expands Sunscreen Options for the First Time in 20 Years

Endpoints NewsPharma and biotech salaries: Top-paying companies of 2025

FierceBiotechRoche sticks with €600M diagnostics investment in Germany but warns of future risk

10x Genomics Blog10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocus

FierceBiotechCeQur nabs $100M series E to fuel insulin patch commercialization

10x Genomics News10x Genomics acquires Proteintech Genomics division - Investing.com

PharmaVoiceWith a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark